CancerDrs

Lymphoma clinical trials in Kansas

16 actively recruiting lymphoma trials at 26 sites across Kansas.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in Kansas:
  • HaysMed — Hays, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • Lawrence Memorial Hospital — Lawrence, Kansas
  • Veteran Administration Eastern Kansas Healthcare — Leavenworth, Kansas
  • The University of Kansas Cancer Center - Olathe — Olathe, Kansas
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Kansas:
  • Wesley Medical Center — Wichita, Kansas
Phase 3 Recruiting Academic/Other

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in Kansas:
  • Cancer Center of Kansas - Chanute — Chanute, Kansas
  • Cancer Center of Kansas - Dodge City — Dodge City, Kansas
  • Cancer Center of Kansas - El Dorado — El Dorado, Kansas
  • Cancer Center of Kansas-Independence — Independence, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
Phase 3 Recruiting Industry

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the se…

Sponsor: Lyell Immunopharma, Inc.
NCT ID: NCT07188558
Sites in Kansas:
  • University of Kansas Cancer Center — Westwood, Kansas
Phase 2 Recruiting Industry

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal re…

Sponsor: Allogene Therapeutics
NCT ID: NCT06500273
Sites in Kansas:
  • The University of Kansas Hospital — Kansas City, Kansas
Phase 2 Recruiting NIH

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05886036
Sites in Kansas:
  • University of Kansas Cancer Center — Kansas City, Kansas
  • University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
  • University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
Phase 1, Phase 2 Recruiting NIH

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07069699
Sites in Kansas:
  • University of Kansas Clinical Research Center — Fairway, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
  • University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
Phase 1 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Kansas:
  • University of Kansas Clinical Research Center — Fairway, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
Phase 1 Recruiting Industry

SynKIR-310 for Relapsed/Refractory B-NHL

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

Sponsor: Verismo Therapeutics
NCT ID: NCT06544265
Sites in Kansas:
  • The University of Kansas Cancer Center — Fairway, Kansas
Phase 1 Recruiting Academic/Other

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in …

Sponsor: University of Kansas Medical Center
NCT ID: NCT03533816
Sites in Kansas:
  • University of Kansas Cancer Center — Westwood, Kansas
Phase 1 Recruiting Academic/Other

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

This multicenter phase 1 trial with "3 + 3" dose escalation design seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of chimeric antigen receptors targe…

Sponsor: University of Kansas Medical Center
NCT ID: NCT06879340
Sites in Kansas:
  • University of Kansas Cancer Center — Westwood, Kansas
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Kansas:
  • Central Care Cancer Center - Garden City — Garden City, Kansas
  • Central Care Cancer Center - Great Bend — Great Bend, Kansas
  • Veteran Administration Eastern Kansas Healthcare — Leavenworth, Kansas
  • Mercy Hospital Pittsburg — Pittsburg, Kansas
  • Cotton O'Neil Cancer Center / Stormont Vail Health — Topeka, Kansas
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Kansas:
  • HaysMed — Hays, Kansas
  • Lawrence Memorial Hospital — Lawrence, Kansas
  • The University of Kansas Cancer Center - Olathe — Olathe, Kansas
  • University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
  • University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
Recruiting Network

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer …

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06002828
Sites in Kansas:
  • Central Care Cancer Center - Garden City — Garden City, Kansas
  • Central Care Cancer Center - Great Bend — Great Bend, Kansas
  • HaysMed — Hays, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • Lawrence Memorial Hospital — Lawrence, Kansas

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27